DNA methylation is a highly studied epigenetic signature that is associated with regulation 2 of gene expression, whereby genes with high levels of promoter methylation are generally 3 repressed. Genomic imprinting occurs when one of the parental alleles is methylated, i.e, 4 when there is inherited allele-specific methylation (ASM). A special case of imprinting occurs 5 during X chromosome inactivation in females, where one of the two X chromosomes is silenced, 6 in order to achieve dosage compensation between the sexes. Another more widespread form 7 of ASM is sequence dependent (SD-ASM), where ASM is linked to a nearby heterozygous 8 single nucleotide polymorphism (SNP). 9 We developed a method to screen for genomic regions that exhibit loss or gain of ASM in 10 samples from two conditions (treatments, diseases, etc.). The method relies on the availability 11 of bisulfite sequencing data from multiple samples of the two conditions. We leverage other 12 established computational methods to screen for these regions within a new R package called 13 DAMEfinder. It calculates an ASM score for all CpG sites or pairs in the genome of each 14 sample, and then quantifies the change in ASM between conditions. It then clusters nearby 15 CpG sites with consistent change into regions. 16 In the absence of SNP information, our method relies only on reads to quantify ASM. 17 This novel ASM score compares favourably to current methods that also screen for ASM. Not 18 only does it easily discern between imprinted and non-imprinted regions, but also females 19 from males based on X chromosome inactivation. We also applied DAMEfinder to a colorectal 20 cancer dataset and observed that colorectal cancer subtypes are distinguishable according to 21 their ASM signature. We also re-discover known cases of loss of imprinting. 22 We have designed DAMEfinder to detect regions of differential ASM (DAMEs), which 23 is a more refined definition of differential methylation, and can therefore help in breaking 24 down the complexity of DNA methylation and its influence in development and disease. 25 Background 26 Epigenetic modifications refer to mitotically-heritable, chemical variations in DNA and 27 chromatin in the absence of changes in the DNA nucleotide sequence itself [1, 2]. Although 28 there are a large number of such documented phenomena, DNA methylation (i.e., methyl 29 groups added to cytosines in mammalian DNA, mostly in CpGs dinucleotides) stands out 30 because the mechanism of heritability, via maintenance methyltransferases, is well-determined 31 [3] [4][5]. In addition, due to well-known effects of chemical reactions, such as sodium bisulfite 32 conversion of cytosines to uracils [6], and biochemical reactions like TET-pyridine borane 33 conversion of 5-methylcytosine to dihydrouracil [7], the interrogation of DNA methylation 34 level across the genome can be sampled and quantified at each cytosine.
. The DAMEfinder pipeline. A. Files necessary to run DAMEfinder are reported in yellow rectangles. White rectangles show the main R outputs from DAMEfinder. Steps to be run before DAMEfinder are in the circle, i.e., fastq files undergo quality control and read alignment with bismark [42]. The resulting bam file is used to calculate an ASM score, which can be done in two ways: B. (i) the tuple-based strategy that takes as input a beforehand created methtuple [40] file. The score is calculated based on the read counts of pairs of CpG sites. (ii) the SNP-based strategy, which takes as input both the bam file and a VCF file with heterozygous SNPs. Here the score is calculated for each CpG site in the reads containing a SNP. C. We determine differential ASM by calculating a statistic based on either the tuple ASM or the SNP-ASM (using limma [38] ), which reflects the difference between two conditions (Group A vs. Group B) for each genomic position (tuple or site). DAMEs are defined based on this statistic, as regions of contiguous positions with a consistent change in ASM.
of the CpG sites. Sites that are not in reads containing a SNP are not considered. We 151 calculate ASM i snp for each CpG site i contained in the reads of a SNP as:
where X ir M and X ia M correspond to the number of methylated reads from the reference r allele, 153 and the alternative a allele. In practice, it makes no difference which allele is the reference or 154 the alternative. X ir and X ia correspond to the total number of reads covering the reference 155 and the alternative allele (see schematic in Figure 1B ). The score ranges from 0 to 1, where a i.e., the proportion of methylated reads in a pair of CpG sites or tuple is close to 0.5. We 165 calculate this score as a weighted log-odds ratio:
where X i · corresponds to the number of reads covering a unique pair of CpG sites i, generated allele-specificity, are attenuated to 0. This is calculated as:
where represents the degree of allowed departure from a 50:50 ratio, and θ i : In order to test the ASM tuple score, we used the ASM snp score as an indicator of true ASM, 180 and calculated the ASM tuple score, the allelicmeth and amrfinder scores, and a score 181 representing absolute deviation from 50% methylation (methdeviation; see Methods), in a 182 single normal tissue sample from the colorectal cancer (CRC) dataset (see Methods).
183 Figure 2 shows the true positive rate (TPR) and false positive rate (FPR) achieved by the 4 evaluated scores at 3 different coverage thresholds (left to right), and 2 ASM snp 185 cutoffs (top to bottom). ASM tuple was consistently more sensitive and specific than the other 186 three scores, especially as coverage was increased. Intermediate methylation values yielded 187 comparable results, however the ASM tuple was able to detect more cases of "real" ASM in 188 all combinations. allelicmeth increasingly failed as coverage and ASM snp value increases.
189
amrfinder performed better than allelicmeth at higher true values.
190 Figure 2 . Comparison of the ASM tuple score to allelicmeth, amrfinder and methylation deviation, by considering ASM snp as true ASM. We calculated ASM tuple scores (red), deviations from 50% methylation (blue), allelicmeth scores (green), amrfinder scores (purple) in a sample of normal colorectal mucosa included in the CRC dataset. The scores were compared to each other by plotting the FPR against the TPR achieved. The plots are drawn for different intervals of read coverage (5-9, 10-49, ≥ 50), and different levels of the ASM snp score (≥ 0.5, ≥ 0.8), which is considered the "true" ASM. Overall AUCs (area under the curve) for the top three panels: ASM tuple = 0.83, deviations from 50% = 0.81, allelicmeth = 0.66, amrfinder = 0.68. Overall AUCs for the lower three panels: ASM tuple = 0.82, deviations from 50% = 0.81, allelicmeth = 0.64, amrfinder = 0.72
As an additional validation of the ASM tuple score, we used the blood dataset (see In the same blood dataset, we also compared the ASM tuple scores from the promoters that all CpG positions are not differential. We adjust p c as above.
238
Evaluation of DAME detection 239 We compared the different strategies to control FDR in the DAME detection pipeline, by 240 applying them to a semi-simulated dataset and plotting the TPR and FDR achieved at 241 different adjusted p-value thresholds (0.01, 0.05, 0.1) ( Figure 4 ). We designed a small set of 242 simulated DAMEs to evaluate the FDR control of the above strategies. We took 6 samples 243 of normal tissue from the CRC dataset and calculated ASM snp scores in each of them. We 244 assumed these scores to be the ASM snp baseline in the simulation. Then, we divided the 245 samples into two groups of three samples each, and for all the CpG sites covered by the 6 246 samples, we defined clusters of contiguous CpG sites. For each truly differential cluster, we 247 added signal to a randomly determined subset of adjacent CpG sites (see Methods for more 248 details).
249
Overall, the empirical p-value controlled the FDR, whereas the Simes method tended 250 to be less conservative but more sensitive (Figure 4 and Supplementary Figure 1 (hypermethylated DMRs = 0.57%, hypomethylated DMRs = 0.66%) ( Table 1) .
287 Figure 6 . DAMEs overlapping known loci exhibiting loss of imprinting in colorectal cancer. A. DAME located in chr14:101,291,540-101,293,480, upstream the imprinted MEG3 gene. The loss of imprinting was significant in both types of CRCs. B. DAME located in chr11:2,021,017-2,021,260, upstream the imprinted H19 gene. Loss of imprinting only occurred in CIMP CRCs. C. DAME in the GNAS gene located in chr20:57,425,758-57,428,036. Loss of imprinting was detected in both types of CRCs. Y-axis in all panels corresponds to ASM tuple means. Lines connect means at intermediate positions between a pair of CpG sites. Shared areas correspond to confidence intervals at each position (standard errors of the mean). We used data generated by the Blueprint Consortium. We downloaded raw paired-end 405 fastq files from venous blood of 3 healthy females and 3 healthy males (CD14-positive,
406
CD16-negative classical monocyte, EGA dataset: EGAD00001002523). 
